China

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

MindRank developed MAP as an AI-native drug discovery engine that combines computational biology, chemistry, laboratory experiments and clinical data into a single research platform.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.

The new collaboration centres on CSPC’s small interfering RNA (siRNA) drug discovery platform and its proprietary delivery technology, which is designed to transport therapies beyond the liver.

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.

The decision makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.

The approval adds a new option in the growing IL-17 inhibitor class and strengthens the company’s dermatology portfolio.

The company officially listed on the Hong Kong Stock Exchange on June 5, achieving a market valuation of approximately HK$10.7 billion (US$1.37 billion) following its debut.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.